Volver a Agenda
Session 10: Hot Topics in Oligonucleotide Therapeutics
Session Chair(s)
Arthur A. Levin, PHD
Distinguished Scientist, Avidity Biosciences, United States
As we learn more about RNA biology, its importance in the regulation of gene expression, and its role in disease processes, it is becoming clear there are many more ways to use oligonucleotides as therapeutic agents. With the identification of novel exploitable mechanism of RNA modulation, the range of diseases that can be targeted increases. This session will explore multiple novel ways to modulate RNA biology that may ultimately be used as a way to address disease processes and become the foundation for new therapeutic agents.
Learning Objective :
Speaker(s)
Session Co-Chair
Pharmacologist, Office of New Drug, CDER, FDA, United States
Antisense-Mediated Control of RNA Splicing to Treat Monogenic Diseases
Chief Executive Officer, Stoke Therapeutics Inc., United States
A to I Editing and Neuronal Plasticity
Senior Scientist, Marine Biological Laboratory, United States
A Site-Directed RNA Editing Strategy to Correct Genetic Mutations
Post Doctoral Fellow, The Marine Biological Laboratory, University of Chicago, United States
Stereodefined LNA Phosphorothioates: A New Perspective in RNA Therapeutics
VP, Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen, Denmark
¿Tiene una cuenta?